HC Wainwright Reiterates Buy Rating for Actinium Pharmaceuticals (NYSE:ATNM)

Actinium Pharmaceuticals (NYSE:ATNM)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $4.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 113.90% from the company’s current price.

Actinium Pharmaceuticals Stock Performance

ATNM opened at $1.87 on Tuesday. The stock has a market capitalization of $58.34 million, a PE ratio of -1.35 and a beta of 0.10. The stock’s 50 day moving average price is $1.23 and its 200-day moving average price is $1.45. Actinium Pharmaceuticals has a 52-week low of $1.03 and a 52-week high of $10.24.

Hedge Funds Weigh In On Actinium Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ATNM. Geode Capital Management LLC grew its holdings in shares of Actinium Pharmaceuticals by 3.0% during the 3rd quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock worth $1,290,000 after acquiring an additional 19,843 shares during the period. Northern Trust Corp grew its stake in Actinium Pharmaceuticals by 4.9% in the fourth quarter. Northern Trust Corp now owns 251,930 shares of the company’s stock worth $317,000 after purchasing an additional 11,812 shares during the period. Los Angeles Capital Management LLC raised its holdings in Actinium Pharmaceuticals by 25.0% in the fourth quarter. Los Angeles Capital Management LLC now owns 213,950 shares of the company’s stock worth $270,000 after purchasing an additional 42,770 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Actinium Pharmaceuticals by 49.9% in the fourth quarter. Renaissance Technologies LLC now owns 190,400 shares of the company’s stock worth $240,000 after purchasing an additional 63,400 shares in the last quarter. Finally, Squarepoint Ops LLC lifted its position in Actinium Pharmaceuticals by 25.4% during the fourth quarter. Squarepoint Ops LLC now owns 183,262 shares of the company’s stock valued at $231,000 after buying an additional 37,159 shares during the period. 27.50% of the stock is owned by institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).